Veru is a Miami-based drug developer working on enobosarm for obesity and sabizabulin for inflammatory heart disease. It last closed at $2.14 on Nov 17, up 2.88% on the day. VERU reports earnings on Thu, Nov 26, 2026.
Only 1 firm rated VERU in the past 90 days, not enough for a consensus
Average 12-month target
$28.00
▲ 1208.4% upside
Based on 1 analyst who set a price target on VERU in the past 90 days. The average target is $28.00, with a high of $28.00 and a low of $28.00, compared with the last close of $2.14.
Low $28.00Avg $28.00High $28.00
Blue marker: last close $2.14
Highest target$28.00
Average target$28.00
Lowest target$28.00
Latest rating changes
WestPark CapitalInitiated
Oct 6Buy$28
Canaccord GenuityMaintained
Jun 4Buy$25
Date
Firm
Action
Rating
Price target
Oct 6
WestPark Capital
Initiated
Buy
$28
Jun 4
Canaccord Genuity
Maintained
Buy
$25
Loading…
Technical Analysis
VERU · as of the Nov 17 close · updated after every close
Downtrend
The stock is 2% below its 20 day and 9% below its 50 day average. It is 15% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot at $2.13, and the nearest resistance the 20 day average at $2.18.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 5.1%/day
Key levels
$7.3352 week high+242.5%
$2.47200 day average+15.4%
$2.46100 day average+15.0%
$2.3350 day average+8.9%
$2.21Swing high (Nov 9)+3.3%
$2.19Pivot R1+2.3%
$2.1820 day average+1.9%
$2.14Last close
$2.13Pivot−0.5%
$2.11Swing low (Jun 4)−1.4%
$2.08Pivot S1−2.8%
$2.0352 week low−5.1%
Indicators
RSI (14)
44.20
Middle of its range
Neutral
MACD
-0.07
Below its signal line
Bearish
Stochastic
21.9
Middle of its range
Neutral
ADX (14)
11.3
No clear trend
Williams %R
-63.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-54.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−0.9%
Change over 10 sessions
Bearish
ATR (14)
$0.11
Typical daily range, 5.1% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityLow, 15.5%/day
Key levels
$7.3352 week high+242.5%
$2.47200 day average+15.4%
$2.46100 day average+15.0%
$2.3350 day average+8.9%
$2.21Swing high (Nov 9)+3.3%
$2.19Pivot R1+2.3%
$2.1820 day average+1.9%
$2.14Last close
$2.13Pivot−0.5%
$2.11Swing low (Jun 4)−1.4%
$2.08Pivot S1−2.8%
$2.0352 week low−5.1%
Indicators
RSI (14)
39.98
Weak, oversold below 30
Neutral
MACD
-0.13
Below its signal line
Bearish
Stochastic
8.8
Near the bottom of its range
Oversold
ADX (14)
35.0
Trending up
Williams %R
-86.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-115.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−12.3%
Change over 10 sessions
Bearish
ATR (14)
$0.33
Typical daily range, 15.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VERU
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how VERU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Earnings in 8 daysSignals right before a report are less reliable. The report can override them.
November seasonalityHow VERU usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How VERU has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VERU is in one of them and how their past VERU trades turned out.
Veru is a drug development company based in Miami, Florida. Its lead candidate, enobosarm, is an oral medicine designed for patients with obesity who take GLP-1 drugs, with the aim of helping them keep muscle while losing fat. Its second candidate, sabizabulin, is being studied as a treatment for inflammation in atherosclerotic cardiovascular disease, a condition in which fatty deposits build up in the arteries. The company's candidates are aimed at patients with these conditions and the doctors who treat them.